Abstract
Non-alcoholic steatohepatitis is a clinical syndrome with pathological changes similar to alcoholic steatohepatitis without a history of excessive alcohol consumption, and is a key stage of reversible progression to liver fibrosis, which can further develop into malignant diseases such as cirrhosis or even liver cancer if preventive measures are not taken. The pathogenesis of NASH is complex, and there are no any effective drugs for NASH. It is difficult for single-target drugs to achieve good therapeutic effects, and are accompanied by strong side effects, and many of them are terminated in the clinical trial stage. Multi-target drugs are not easy to produce drug resistance, and can exert synergistic effects on multiple targets to maximize drug efficacy and minimize adverse side effects, and has a good effect on the treatment of complex diseases. This article summarizes the multi-target drugs for the treatment of NASH, and provides a reference for finding new drugs for the treatment of NASH.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
